Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Tohoku University Hospital /ID# 238433, Sendai

Duplicate_NHO Nagoya Medical Center /ID# 233523, Nagoya

Aichi Cancer Center Hospital /ID# 238797, Nagoya

Duplicate_Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital /ID# 233524, Nagoya

Duplicate_Chiba Cancer Center /ID# 238839, Chiba

National Hospital Organization Shikoku Cancer Center /ID# 234059, Matsuyama

Kyushu University Hospital /ID# 238437, Fukuoka

Duplicate_Hokkaido University Hospital /ID# 238377, Sapporo

Hyogo Prefectural Amagasaki General Medical Center /ID# 234082, Amagasaki-shi

Tokai University Hospital /ID# 238970, Isehara

University Hospital Kyoto Prefectural University of Medicine /ID# 239883, Kyoto

Niigata University Medical & Dental Hospital /ID# 238324, Niigata

Duplicate_Okayama University Hospital /ID# 238467, Okayama

Kindai University Hospital /ID# 234001, Osakasayama-shi

Duplicate_Osaka University Hospital /ID# 234037, Suita-shi

Duplicate_Shimane University Hospital /ID# 234076, Izumo-shi

Duplicate_Jichi Medical University Hospital /ID# 238434, Shimotsuke-shi

National Cancer Center Hospital /ID# 232449, Chuo-ku

The Cancer Institute Hospital Of JFCR /ID# 232450, Koto-ku

Yamagata University Hospital /ID# 234032, Yamagata